Role of Endoscopy in Motility Disorders of Upper Gastrointestinal Tract

Noh, Jin Hee; Jung, Hwoon‐Yong

doi:10.5056/jnm22170

Cited by 3 publications

(2 citation statements)

References 95 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Impaired esophageal clearance prolongs the contact between refluxate and the esophageal mucosa, leading to symptoms and potential damage [ 34 , 35 ]. Esophageal motility disorders, delayed gastric emptying, and reduced defensive properties of the esophageal mucosa also contribute to reflux [ 36 , 37 ].…”

Section: Gastroesophageal Reflux Disease (Gerd)mentioning

confidence: 99%

Chitosan Nanoparticles for Gastroesophageal Reflux Disease Treatment

Herdiana

2023

Polymers

View full text Add to dashboard Cite

Gastroesophageal Reflux Disease (GERD) is a chronic ailment that results from the backward flow of stomach acid into the esophagus, causing heartburn and acid regurgitation. This review explores nanotechnology as a novel treatment approach for GERD. Chitosan nanoparticles (CSNPs) offer several advantages, including biocompatibility, biodegradability, and targeted drug delivery capabilities. CSNPs have been extensively studied due to their ability to encapsulate and release medications in a controlled manner. Different nanoparticle (NP) delivery systems, including gels, microspheres, and coatings, have been developed to enhance drug retention, drug targeting, and controlled release in the esophagus. These nanoparticles can target specific molecular pathways associated with acid regulation, esophageal tissue protection, and inflammation modulation. However, the optimization of nanoparticle formulations faces challenges, including ensuring stability, scalability, and regulatory compliance. The future may see CSNPs combined with other treatments like proton pump inhibitors (PPIs) or mucosal protectants for a synergistic therapeutic approach. Thus, CSNPs provide exciting opportunities for novel GERD treatment strategies.

show abstract

Section: Gastroesophageal Reflux Disease (Gerd)mentioning

confidence: 99%

Chitosan Nanoparticles for Gastroesophageal Reflux Disease Treatment

Herdiana

2023

Polymers

View full text Add to dashboard Cite

show abstract

“…As the population ages and human disease changes, endoscopy has become the most widely used and effective diagnostic modality for gastrointestinal diseases. 1 Colonoscopy is recommended for early cancer detection and prevention, which can significantly reduce mortality. 2 Sedative and analgesic drugs through non-intravenous routes (such as oral anxiolytic medications combined with the use of lidocaine jelly) were previously widely used during colonoscopy.…”

Section: Introductionmentioning

confidence: 99%

The Efficacy and Safety of Remimazolam Besylate Combined with Esketamine for Outpatient Colonoscopy: A Prospective, Randomized, Controlled Clinical Trial

Li,

Zhao,

Hao

et al. 2023

DDDT

View full text Add to dashboard Cite

Evaluate the efficacy and safety of remimazolam besylate combined with esketamine for outpatient colonoscopy. Patients and methods: A total of 150 outpatients undergoing colonoscopy were randomized into two groups. A MOAA/S score ≤3 was maintained. The primary outcome was the rate of successful colonoscopy completion. Time indicators, hemodynamic parameters, the consumption of lidocaine, esketamine, propofol and remimazolam besylate, MOAA/S scores and bispectral index (BIS) values, the lowest SpO 2 , body movement, the use of rescue medication, endoscopist and patient satisfaction, recall of the procedure, mini-mental state examination (MMSE), fatigue level and adverse events were recorded. Results: Procedure completion was equivalent between groups (P > 0.05). Both induction and awakening times were significantly shorter in the P group (P < 0.05). There were no significant differences in colonoscopy time and discharge time (P > 0.05). The lowest SpO 2 was significantly lower in the P group, while the level of fatigue was higher (P < 0.05). Patient satisfaction was significantly higher in the R group (P < 0.05). Endoscopist satisfaction was significantly higher in the P group (P < 0.05). There were no significant differences in both systolic and diastolic blood pressure between groups except at T5 and T6 (P > 0.05). Both HR and RR were significantly lower in the P group from T3 to T5 (P < 0.05). BIS values were significantly lower in the P group from T3 to T5, while MOAA/S was significantly lower in the P group at T3 and T4 (P < 0.05). Pain on injection was significantly higher in the P group (P < 0.05). Conclusion: Remimazolam besylate has a similar efficacy to propofol when combined with subanesthetic doses of esketamine during outpatient colonoscopy. Remimazolam besylate combined with esketamine resulted in less injection pain and more stable hemodynamics, although it prolonged induction and awakening time.

show abstract